Los puntos clave no están disponibles para este artículo en este momento.
The clinical study of CXCR1/2 inhibitors in combination with adoptively transferred NK cells is warranted.
Greene et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: